Cool Currents Vol. 09
In Q2, proof of control stopped being the shipper's problem. It became everyone's. The mega-carrier's cross-dock, the clinic that had never read the statute, the patient's front door.
Last quarter's theme was that the modernization conversation had stopped being voluntary. DSCSA, FSMA 204, and a wave of capital all pointed at the same destination: end-to-end proof of control. Q2 answered the follow-up question nobody had asked out loud: Mandatory for whom?
Three times over, the answer was everyone. The FDA used DSCSA to reach a category of business that had almost certainly never read the statute. Therapies kept moving toward patients' homes, where there is no validated refrigerator and no trained operator. And the largest healthcare logistics provider in the world spent real money to shore up its handoffs, which is a fairly loud admission about where the risk had been sitting all along.
The through line is handoffs, which is where cold chain often fails. The industry keeps adding parts to the chain, and every one it adds is another pair of hands, another seam, another place the proof has to hold. The handoffs are multiplying.
The FDA took DSCSA somewhere nobody expected
What happened: In April, the FDA issued what appears to be the first DSCSA warning letter ever directed at a "dispenser" and the recipient was not a pharmacy. It was a medical spa. The agency alleged two violations: the facility transacted with unauthorized trading partners, and it handled products without the required product identifier. The method is the part that travels. The FDA obtained purchase records directly from the drug's manufacturer, set them against the facility's own patient treatment records, and found that the spa had administered substantially more product than its legitimate purchases could account for. The only unusually large order on file was dated after inspectors had already arrived.
Why it matters: Under DSCSA, "dispenser" means any person authorized to dispense or administer prescription drugs. That sweeps in clinics, providers, and practitioners who have never thought of themselves as regulated trading partners, and who have none of the documentation infrastructure the law assumes. The enforcement technique travels further than the target. The FDA reconciled two independent record sets and treated the gap between them as the finding. Any operation whose paper trail cannot be squared with what physically happened is carrying that same gap, whether or not anyone has looked yet.
Our take: This is the proof-of-control principle with an enforcement arm attached. Reconciliation is the whole game. Paperwork that cannot be squared with what physically happened will eventually get squared by somebody else, on their schedule.
The last mile became the patient's doorstep
What happened: Direct-to-patient models moved from pilot to operating reality. A May feature in Contract Pharma gathered CDMOs and logistics practitioners on what that actually demands, and their consensus was blunt: delivering to a hospital is predictable; delivering to a home is not. Homes are not controlled environments. Patients are not logistics professionals. At-home storage is unqualified and highly variable, and the people receiving these shipments are not trained GDP operators. Nearly half of new pharmaceutical products launched globally through 2027 are expected to require cold chain storage.
Why it matters: The burden of proof now runs to the doorstep. Packaging has to absorb variability rather than resist it. Monitoring has to shift from retrospective validation (reading the logger after the fact) to real-time visibility that permits intervention before the patient is affected. Chain of custody has to survive a kitchen. As one practitioner put it: if the system relies on the patient to compensate for its complexity, it is the wrong system.
Our take: Control that stops at the depot leaves the least predictable hour of the journey unaccounted for. Real-time visibility is what turns a front porch into a valid endpoint rather than a blind spot.
The biggest player started buying the argument
What happened: On June 22, UPS announced a $48 million investment in 27 temperature-controlled freight cross-dock facilities across the US, Europe, Asia, and the Americas. All IATA CEIV Pharma-compliant, covering 2–8°C, 15–25°C, and frozen. In their own words: a single integrated network "eliminates handoffs between providers, reducing risk and increasing control," backed by a 24/7 control tower that "proactively monitors shipments, flags risks and enables rapid intervention." The investment sits on top of acquisitions that brought in Bomi Group, Frigo-Trans, and Andlauer.
Why it matters: When the largest healthcare logistics provider in the world spends $48 million specifically to remove handoffs and buy proactive intervention, it settles the argument about where cold chain risk actually lives. It also raises the floor. Proactive monitoring and intervention are moving from differentiator to table stakes. The mechanism is worth understanding, though. Consolidation removes handoffs by owning more of the chain. That works for shipments that stay inside one network. Most shipments do not.
Our take: Two ways to survive a handoff. Own every part in the chain, or make the shipment carry its own control and its own record so it stops mattering who is holding it. Only one of those scales to the networks you will never own.
One number to know
Nearly half of new pharmaceutical products launched globally through 2027 are expected to require cold chain storage (Cencora, via Contract Pharma, May 2026). The share of medicine that has to stay inside a tight band keeps climbing. It climbs fastest in the therapies with the least tolerance for one bad hour.
What we're watching in the back half of 2026
The dry ice supply question is unresolved. As of late 2025, US production ran at roughly 4,600 tons per day while demand had been growing about 5% annually for nearly a decade. California (one of the country's leading CO2 suppliers) was set to lose close to 850 tons per day of capacity as three plants shut down between the end of 2025 and April 2026 (Intelligas Consulting, via Packaging Dive). Whether that translates into a genuine 2026 shortage is the open question. If any part of your network runs on dry ice, this one is worth watching closely.
The other is the DSCSA deadline in November. Small dispensers (pharmacies with 25 or fewer licensed pharmacists or technicians) have to comply by November 27, 2026, after the large-dispenser grace period expired in November 2025. Given what the FDA did to a medical spa in April, "we didn't think it applied to us" is not a durable position.
One thing worth reading
"Cold Chain Logistics Enters the Patient-Centric Era" (Contract Pharma, May 2026). A clear-eyed survey of how direct-to-patient delivery is forcing a redesign of cold chain, with practitioners describing exactly what breaks at the last mile and why real-time visibility is becoming the difference between a delivery and a treatment.
Cool Currents is Artyc's quarterly perspective on what changed in cold chain and why it matters. Not a company update. A signal report for operators who don't have time to track everything themselves.